The blend holds no licensed-medicine status, which means there is no approved dosing label, no sanctioned route of administration, and no validated schedule anywhere in the regulatory record. What circulates instead is a body of self-directed practice: a freeze-dried vial reconstituted at home with bacteriostatic water, drawn into an insulin syringe, and self-injected, most often subcutaneously into abdominal fat. The microgram figures attached to that practice trace back to forums, coaches, and sellers rather than to any clinical dose-finding trial, and none of it is medical guidance.
The BPC-157/TB-500 blend has no FDA-approved dose, route, or dosing schedule, and every circulating protocol originates from user communities and vendors rather than from clinical dose-finding trials.
Reconstitution turns a shelf-stable powder into an injectable liquid, and in this setting it happens entirely at the household level with no pharmacist in the loop. The circulating procedure is precise about mixing technique, yet that technique governs only sterility and dissolving; it never confirms what the powder actually is.
Bacteriostatic water is used because its benzyl alcohol preservative lets a multi-dose vial be entered repeatedly over days or weeks, but careful reconstitution verifies neither the identity, purity, nor quantity of the peptide inside.
Subcutaneous injection into the fatty layer just under the skin is the route described most often, delivered through a short, fine insulin needle set at a shallow angle into a pinched fold of abdominal fat a couple of inches from the navel. Two other approaches appear in user accounts, intramuscular injection and deliberate injection near a specific injured area, though no controlled human study has shown that site-of-injury delivery changes the outcome versus a systemic subcutaneous dose.
| Route | How it is described | Evidence status |
|---|---|---|
| Subcutaneous | Shallow needle into a pinched abdominal fat fold | Most commonly reported; no clinical validation |
| Intramuscular | Needle placed into muscle tissue | Reported by some users; no comparative human data |
| Site-of-injury | Injection near a specific injured area | Local-concentration theory; unproven in controlled studies |
Subcutaneous injection into abdominal fat is the most commonly reported route, and aseptic measures such as swabbing the stopper and skin, using a fresh needle each time, and rotating sites are the main way self-injectors attempt to limit infection, abscess, and scarring.
Measuring a dose reduces to arithmetic the user performs by hand, and the syringe is more honest than it looks: insulin units are a volume scale, where one hundred units equal one milliliter, not a peptide scale. A precisely drawn line therefore measures liquid exactly while saying nothing certain about the mass of drug carried in that liquid.
Volume maps to a known mass of peptide only if the vial's label is accurate, so at the microgram scale a small misjudged diluent volume, an air bubble, or needle residue can shift the delivered amount by a meaningful fraction while the syringe still reads as precise.
The dosing protocols in circulation did not come from clinical dose-finding research, and their real origin is what decides how much weight they can carry. They trace to three overlapping sources, one of which has a direct financial stake in how much product gets consumed.
A vendor dosing suggestion is a commercial message rather than a clinical recommendation, because a dose-finding study varies the dose in controlled subjects and measures response and toxicity, none of which a thread of self-reports or a seller's insert can do.
No approved dose exists because neither peptide has completed the human trial process that would produce one, and the blend as a combination has been studied even less. Most of what gets cited sits at the weakest tiers of evidence, and combining two unapproved peptides compounds the uncertainty rather than averaging it out.
Without completed human trials there is no defined therapeutic window for the blend, meaning no established boundary separates an amount too low to matter, an amount that might act, and an amount that causes harm.
Even a perfectly measured injection can deliver an unknown amount, because the number printed on the vial is a claim from an unregulated supplier rather than a verified fact. Products sold outside the pharmaceutical system are frequently found to hold more, less, or different material than labeled, so the real variable is not how carefully the syringe is drawn but what is actually present in the liquid.
Content uncertainty sits underneath every dosing calculation, so the most careful microgram math still rests on a mass and identity of peptide that was never confirmed.
The figures that circulate are worth setting down plainly, precisely so their anecdotal status stays visible and none of them reads as instruction. In user communities doses are expressed in micrograms of each peptide, taken daily or a few times per week and grouped into multi-week cycles followed by a break, and the two peptides are usually framed differently from one another.
| Reported dimension | BPC-157 | TB-500 |
|---|---|---|
| Typical frequency | Framed more often as a daily dose | Framed more often as a few doses per week |
| Phase pattern | Heavier early "loading" stretch, then lighter maintenance | Loading-then-maintenance framing at a weekly cadence |
| Cross-source spread | Amounts and cycle lengths vary widely between sources | Amounts and cycle lengths vary widely between sources |
The wide spread in reported amounts and cycle lengths from one source to another reflects the absence of any authoritative number, so every specific figure is a record of what some people say they have done rather than a dose to copy.
Self-directed dosing stacks several categories of risk on top of one another, running from the mechanical to the systemic to the structural. The layer beneath all of them is the absence of a clinician watching for early harm, which is the safety net formal treatment provides and self-dosing removes.
With no defined therapeutic window and no clinical monitoring, a person self-dosing the blend can at once exceed any amount evidence has examined and receive a dose that does nothing, with no marker to tell which, and the published guidance is that new or worrying symptoms are a reason to stop and consult a qualified medical professional.
Educational use only. This article describes what the published scientific and clinical literature reports about BPC-157/TB-500 Blend. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
